WWW.EXFILE.COM, INC. -- 14991 -- BOSTON SCIENTIFIC CORP. -- FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
 
 
FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
 
Date of Report (Date of earliest event reported):     March 1, 2007

 
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)

DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
    

One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code:  (508) 650-8000
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

ITEM 7.01.
REGULATION FD DISCLOSURE.
 
On March 5, 2007, Boston Scientific Corporation (the “Company”) issued a press release announcing a request for information received on March 1, 2007, from Representative Henry A. Waxman, Chairman of the Committee on Oversight and Government Reform of the U.S. House of Representatives, about the Company’s TAXUS® paclitaxel-eluting coronary stents. A copy of the press release is furnished with this report as Exhibit 99.1. A form of the request letter is furnished with this report as Exhibit 99.2.


The information in this Current Report on Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01.
FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit No.
Description

99.1
Press Release issued by Boston Scientific Corporation dated March 5, 2007.
99.2
Form of Letter from the Committee on Oversight and Government Reform dated February 28, 2007.
 
-2-

SIGNATURE


Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
     
  BOSTON SCIENTIFIC CORPORATION
 
 		  
 		  
 
Date:       March 6, 2007 By:   /s/ Lawrence J. Knopf
 
Lawrence J. Knopf
 
Vice President and Assistant General Counsel
 
 
 
 
 
 
 

 
 
 
 
 

 
-3-
 

INDEX TO EXHIBITS


Exhibit No.
Description

99.1
Press Release issued by Boston Scientific Corporation dated March 5, 2007.
99.2
Form of Letter from the Committee on Oversight and Government Reform dated February 28, 2007.
 
-4-